Effect of delayed administration of activated charcoal on the absorption of conventional and slow-release verapamil.

OBJECTIVE To investigate the effect of simultaneous and delayed administration of activated charcoal on the absorption of two verapamil formulations. METHODS In the first study, 9 healthy volunteers received the following treatments: 1) verapamil 80 mg (conventional formulation) with 50 mL water only, 2) verapamil 80 mg and 25 g activated charcoal immediately afterwards, and 3) verapamil 80 mg with 50 mL water, followed by 25 g charcoal 2 h after verapamil ingestion. In the second study, 8 healthy volunteers received the following treatments: 1) verapamil 240 mg (slow-release formulation) with 50 mL water only, 2) verapamil slow-release 240 mg and 25 g activated charcoal immediately afterwards, 3) verapamil slow-release 240 mg with 50 mL water, followed by 25 g charcoal 2 h after verapamil ingestion, and 4) verapamil slow-release 240 mg with 50 mL water, followed by 25 g charcoal 4 h later. Plasma verapamil concentrations over 24 h were measured by high performance liquid chromatography. RESULTS Activated charcoal given immediately after the conventional formulation of verapamil reduced the AUC0-24 h by 99% (p < 0.0005) and the Cmax by 98% (p < 0.0005). When the administration of charcoal was delayed 2 h, no significant change in verapamil absorption was observed. With the slow-release formulation of verapamil, charcoal given immediately after verapamil ingestion reduced the verapamil AUC0-24 h by 86% (p = 0.001) and the Cmax by 82% (p = 0.002). When the administration of charcoal was delayed 2 or 4 h, the AUC0-24 h was reduced by 35% (p = 0.04) and 32% (p = 0.001), respectively, but the Cmax was decreased by 13% (p = NS) and 9% (p = NS) only. CONCLUSIONS Activated charcoal was effective in preventing absorption of verapamil when it was administered immediately after verapamil ingestion. In the case of slow-release formulation, charcoal reduced verapamil absorption by over 30% even when given 4 h after verapamil.

[1]  I. Laakso,et al.  Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration. , 1997, British journal of clinical pharmacology.

[2]  I. Whyte,et al.  Overdose with calcium channel blockers , 1994, BMJ.

[3]  I. Whyte,et al.  Calcium Channel Blockin Drug Overdose: an Australian Series , 1994, Human & experimental toxicology.

[4]  T. Litovitz,et al.  1992 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. , 1993, The American journal of emergency medicine.

[5]  A. Dawson,et al.  Unusual results of brown snake envenomation , 1993, The Medical journal of Australia.

[6]  H. Spiller,et al.  A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. , 1993, Annals of emergency medicine.

[7]  N. Buckley,et al.  Slow‐release verapamil poisoning , 1993, The Medical journal of Australia.

[8]  L. Dziukas,et al.  Drug overdose — reducing the load , 1992, The Medical journal of Australia.

[9]  P. Alguire,et al.  Case report: fatal overdose with sustained-release verapamil. , 1992, The American journal of the medical sciences.

[10]  R. Ferner,et al.  Pharmacokinetics and Toxic Effects of Diltiazem in Massive Overdose , 1989, Human toxicology.

[11]  L. Kirshenbaum,et al.  Whole‐bowel irrigation versus activated charcoal in sorbitol for the ingestion of modified‐release pharmaceuticals , 1989, Clinical pharmacology and therapeutics.

[12]  D. McTavish,et al.  Verapamil , 2012, Drugs.

[13]  P. Neuvonen,et al.  Treatment of intoxications using single and repeated doses of oral activated charcoal. , 1989, Journal de toxicologie clinique et experimentale.

[14]  H. Jaeger,et al.  Quantitative determination of verapamil and metabolites in human serum by high-performance liquid chromatography and its application to biopharmaceutic investigations. , 1989, Arzneimittel-Forschung.

[15]  U. Bondesson,et al.  Liquid-chromatographic quantification compared with gas-chromatographic-mass-spectrometric determination of verapamil and norverapamil in plasma. , 1988, Clinical chemistry.

[16]  P. Neuvonen,et al.  Oral Activated Charcoal in the Treatment of Intoxications , 1988, Medical toxicology and adverse drug experience.

[17]  D. T. Lim,et al.  Absorption inhibition and enhancement of elimination of sustained-release theophylline tablets by oral activated charcoal. , 1986, Annals of emergency medicine.

[18]  J. Kenny Calcium channel blocking agents and the heart. , 1985, British medical journal.

[19]  M. Scheinin,et al.  Effect of single and repeated doses of activated charcoal on the pharmacokinetics of doxepin. , 1985, International journal of clinical pharmacology, therapy, and toxicology.

[20]  P. Neuvonen,et al.  Do gastric contents modify antidotal efficacy of oral activated charcoal? , 1984, British journal of clinical pharmacology.

[21]  R. Braithwaite,et al.  EFFECT OF ACTIVATED CHARCOAL ON ABSORPTION OF NORTRIPTYLINE , 1977, The Lancet.